ABCG2 and chronic myelogenous leukemia, BCR-ABL1 positive: Similarly, Omran et al. [55] and Rajamani et al. [5] reported no significant influence of the ABCG2 C421A SNP on imatinib response in Egyptian and Indian CML patients, respectively.